Fexinidazole

Kathryn Dzintars, Pharm.D., BCPS
Fexinidazole is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or .

Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • First-stage (hemolymphatic) and second-stage (meningoencephalitic) human African trypanosomiasis (HAT) due to T. brucei gambiensein patients 6 years of age and older who weigh at least 20 kg.
  • Due to decreased efficacy observed in patients with severe second-stage HAT, fexinidazole should only be used in these patients if no other options are available.
  • This drug was developed as part of the Drugs for Neglected Diseases initiative.

-- To view the remaining sections of this topic, please or --

INDICATIONS

FDA

  • First-stage (hemolymphatic) and second-stage (meningoencephalitic) human African trypanosomiasis (HAT) due to T. brucei gambiensein patients 6 years of age and older who weigh at least 20 kg.
  • Due to decreased efficacy observed in patients with severe second-stage HAT, fexinidazole should only be used in these patients if no other options are available.
  • This drug was developed as part of the Drugs for Neglected Diseases initiative.

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: October 19, 2022